Transaction Search Form: please type in any of the fields below.
Date: November 25, 2024 Mon
Time: 8:15 pm
Time: 8:15 pm
Results for prescription drug monitoring
2 results foundAuthor: Clark, Thomas Title: Prescription Drug Monitoring Programs: An Assessment of the Evidence for Best Practices Summary: The role of state prescription drug monitoring programs (PDMPs) in facilitating appropriate prescribing of controlled prescription drugs and helping to address the prescription drug abuse epidemic has been highlighted in recent studies and in the 2011 White House Office of National Drug Control Policy’s Prescription Drug Abuse Prevention Plan (GAO, 2002; Pradel et al., 2009; Baehren et al., 2010; Katz et al., 2010; Johnson et al., 2011; Office of National Drug Control Policy, 2011). A special concern for PDMPs is the diversion of opioid pain relievers into nonmedical use and abuse. A PDMP is a statewide electronic database that gathers information from pharmacies on dispensed prescriptions for controlled substances (most states that permit practitioners to dispense also require them to submit prescription information to the PDMP). Many PDMPs now provide secure online access to this information for authorized recipients. Prescription data (usually for the past year, and including information on date dispensed, patient, prescriber, pharmacy, medicine, and dose) are made available on request from end users, typically prescribers and pharmacists, and sometimes distributed via unsolicited reports. Recipients of PDMP data may also include practitioner licensure boards, law enforcement and drug control agencies, medical examiners, drug courts and criminal diversion programs, addiction treatment programs, public and private third-party payers, and other public health and safety agencies. States vary widely in which categories of users are permitted to request and receive prescription history reports and under what conditions. PDMPs represent a substantially underutilized resource in efforts to improve public health outcomes and address prescription drug abuse (Katz et al., 2010). Key reasons for this underutilization include differences in the data PDMPs collect, whether and how they ensure data quality, the kinds of data analyses and reports they produce, to which users and under what conditions they make data available, and differences in an array of other procedures and practices. With respect to many of these practices, there is not widespread understanding of which constitute “best practices”; that is, which practices are associated with maximizing PDMP effectiveness. The purpose of this white paper is to describe what is known about PDMP best practices, describe and assess the evidence supporting their identification as best practices, and document the extent to which PDMPs have implemented these practices. The paper is structured as follows: • Section II provides background on the history of PDMPs and a conceptual framework for assessing their effectiveness. The contexts in which PDMPs developed have been an important influence on the range of PDMP practices and the extent of their current adoption. Practices can be organized in terms of PDMP workflow and functions (e.g., data collection, analysis, and reporting). Their effectiveness can be assessed by observing their differential impact in achieving intermediate objectives, such as increasing the utilization of PDMPs by all appropriate end users, and ultimate goals, such as improving patient health and reducing the diversion of prescription drugs into illegal use (drug diversion) and overdose. • Section III provides an overview of the paper’s methods and discusses types of evidence for effectiveness, the relative strength of the methods and evidence, and how the current evidence base for potential PDMP best practices was assessed. • Section IV describes candidate PDMP best practices, the extent to which they are implemented by PDMPs, and the evidence base for each practice, and identifies barriers to their adoption. • Section V discusses conclusions and recommendations regarding PDMP best practices. It includes a table summarizing the types of evidence that currently exist for each practice and the strength and consistency of evidence within those types. This section also outlines a research agenda, suggesting the kinds of studies needed to produce a stronger evidence base for practices we believe have the greatest potential to improve PDMP effectiveness. • Section VI provides the references we have examined in developing this white paper. These references are summarized in two tables in an appendix: one providing an overview of the peer-reviewed, published literature on PDMP practices and effectiveness, and a second providing an overview of other literature of evaluation studies and reports, case studies, anecdotal information, and expert opinion. Details: Washington, DC: Pew Charitable Trusts, 2012. 100p. Source: Internet Resource: Accessed September 25, 2012 at: http://www.pewhealth.org/uploadedFiles/PHG/Content_Level_Pages/Reports/PDMP_Full%20and%20Final.pdf Year: 2012 Country: United States URL: http://www.pewhealth.org/uploadedFiles/PHG/Content_Level_Pages/Reports/PDMP_Full%20and%20Final.pdf Shelf Number: 126443 Keywords: Drug Abuse and AddictionDrug Abuse PreventionPrescription Drug AbusePrescription Drug Monitoring |
Author: Reichert, Jessica Title: Opioid Prescribing in Illinois: Examining Prescription Drug Monitoring Program Data Summary: Almost three times as many opioids are prescribed in the United States today as compared to 1999. Health care practitioners wrote 259 million prescriptions for opioid pain medication in 2012, which is enough to provide a full bottle of pills for almost every adult in the country. An estimated one in five patients with pain symptoms who go to their doctor's office receive an opioid prescription. In a 2015 national survey, 13 percent of adults who report taking prescription opioids also reported misuse (defined as non-medical use). Of those, 41 percent obtained opioids for free from friends or relatives. Illinois opioid prescribing is relatively low compared to other states. According to the Centers for Disease Control and Prevention, Illinois ranked 41st out of 50 states and District of Columbia on opioid prescription totals. However, prescription rates vary greatly by county, city, and medical practitioner. This article describes Illinois opioid prescription practices using Illinois Prescription Monitoring Program (ILPMP) data, focusing on trends and prescribing variations by county. A review of available research on the association between opioid prescribing, opioid misuse, and opioid use disorders also is summarized. Policy and practice implications also are included. Details: Chicago: Illinois Criminal Justice Information Authority, 2018. 21p. Source: Internet Resource: Accessed July 2, 2018 at: http://www.icjia.state.il.us/assets/articles/PMP_Article_050918.pdf Year: 2018 Country: United States URL: http://www.icjia.state.il.us/assets/articles/PMP_Article_050918.pdf Shelf Number: 150756 Keywords: Drug Abuse and AddictionOpioid EpidemicOpioidsPrescription Drug AbusePrescription Drug Monitoring |